SFL’s Head Regulatory Affairs Anja Bührer and Senior Regulatory Affairs Manager David Berner are attending the Swissmedic Regulatory News Seminar (8 November 2019, Bern), discussing the impact associated with the implementation of the revised Swiss Therapeutic Products Act and Therapeutic Product Ordinance (HMG2 / HMV4) this year. The seminar will also hold a panel discussion with various stakeholders entitled “Swissmedic – a first wave agency?” on procedural aspect of the drug approval process. They are also looking forward to interacting with other delegates and the Swissmedic authorities in the breakout and the “Meet your Case Manager” sessions.

SFL provides both strategic as well as operational support for projects covering all life-cycle stages from early development to regulatory maintenance and market access of healthcare products, utilizing its unique combination of expertise and a multi-disciplinary approach. In addition, our partner company SFL Pharma provides full support to pharma companies, who do not have a registered subsidiary in Switzerland by acting as Swiss Marketing Authorization Holder (MAH). Contact us to arrange a meeting to discuss how SFL can support your projects.